Eton Pharmaceuticals (ETON) reported Thursday Q2 adjusted earnings of $0.43 per diluted share, up from $0.03 a year earlier.
Two analysts polled by FactSet expected $0.19.
Revenue for the quarter ended June 30 was $37.6 million, up from $18.9 million a year ago.
Four analysts expected $27.1 million.
The company now expects 2026 revenue to exceed $145 million, up from previous guidance of more than $120 million. Four analysts expect $121.3 million.